{
    "Trade/Device Name(s)": [
        "VIDAS TBI (GFAP, UCH-L1)",
        "VIDAS TBI (GFAP)",
        "VIDAS TBI (UCH-L1)"
    ],
    "Submitter Information": "bioM\u00e9rieux Inc",
    "510(k) Number": "K240279",
    "Predicate Device Reference 510(k) Number(s)": [
        "DEN170045"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "QAT"
    ],
    "Summary Letter Date": "May 1, 2024",
    "Summary Letter Received Date": "February 1, 2024",
    "Submission Date": "January 26, 2024",
    "Regulation Number(s)": [
        "21 CFR 866.5830"
    ],
    "Regulation Name(s)": [
        "Brain Trauma Assessment Test"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "Glial Fibrillary Acidic Protein (GFAP)",
        "Ubiquitin C-terminal Hydrolase (UCH-L1)"
    ],
    "Specimen Type(s)": [
        "Serum"
    ],
    "Specimen Container(s)": [
        "Plastic tube with coagulation activator",
        "Plastic tube with rapid coagulation activator",
        "Plastic tube with separator gel (SST)",
        "Plastic tube (CAT)",
        "Plastic tube (with or without separation gel)"
    ],
    "Instrument(s)/Platform(s)": [
        "VIDAS 3 instrument"
    ],
    "Method(s)/Technology(ies)": [
        "Enzyme Linked Fluorescent Assay (ELFA)",
        "Labeled antibody sandwich method",
        "Three-step immunoassay with fluorescent detection"
    ],
    "Methodologies": [
        "Quantitative immunoassay",
        "Automated fluorescent immunoassay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Reagent",
        "Calibrator",
        "Control"
    ],
    "Document Summary": "FDA 510(k) summary for VIDAS TBI (GFAP, UCH-L1) automated ELFA test for quantitative measurement of GFAP and UCH-L1 in serum to aid in mild traumatic brain injury assessment",
    "Indications for Use Summary": "For quantitative measurement of GFAP and UCH-L1 in serum using VIDAS 3, to aid in evaluation of adults (18+ years, within 12 hours of suspected mild traumatic brain injury, GCS 13\u201315) in determining need for head CT scan; a negative result is associated with absence of acute intracranial lesions on CT.",
    "fda_folder": "Immunology"
}